Customer Solutions have developed an automated digital customer loyalty solution named My Member Card (www.mymembercard.no). We believe more loyal customers spend more money and that digital loyalty solutions should be available for every business. My Membercard offers an easy-to-use solution to build customer loyalty. The solution provides a digital customer database with an overview of the loyal customers and tools to keep in touch with them.

OM RUBYNOR AS Kontakt Ole Morten Amundsen på oma@rubynor.com Vi bygger startups! Vi er en dyktig gjeng med utviklere som har troen på seg selv og våre skills med lean startup. Det eneste som mangler er om vi også er hyggelige og har det gøy. team in office Humor er viktig, for startups are hard! Med oss på laget har du startupproffer med god track-record. Med oss som dine kollegaer har du et åpent og ærlig miljø som omfavner utfordringer og usikkerhet, med pågangsmot og trygghet om "dette klarer vi".

Tubeify.tv is the world’s first video site to aggregate videos in a smart and automated way from social media platforms, to provide a full-service website with popular and trending videos, social feeds and merchandise from our video partners. Tubeify.tv does not store any videos in its platform but uses different technologies and business models to partner, source and ingest the most popular videos. Automatic data collection, smart tagging and user behavior tracking provide for enhanced customer experiences and builds engagement Tubeify’s hallmarks include: 1) A well targeted user experience for the Gen ZY audience , with a smart use of data and editors’ curation to show cool and trending videos. 2) An Eshop for creators, influencers and partners’ channel merchandise 3) A branded channel page for video partners’ social media activities Tubeify is Headquartered in Norway, with a skilled management team located in the Nordics, UK, USA and Canada.

Med-Storm's Skin Conductance Algesimeter (SCA) uses the principle of skin conductance to measure pain, allowing us to titrate the right amount of pain medication for each, individual patient. This award-winning technology is not affected by changes in blood circulation, heart rate, hypotensia, environmental temperatures, and hypoxia, and shows low variation between individuals at the same level of pain. The pain monitor can be used on patients as young as 23 weeks of gestational age, as well as geriatric patients. MS is currently working on a miniaturized and wireless version of the SCA.

Supported by Bodø communes næringsfond and Innovasjon Norge; in the Sprint 1 phase of creating a mobile application catering to a worldwide multilingual user base and a commercial customer. The goal is to establish a profitable and expandable product range that will enhance learning by the discovery in a way that triggers competition, exercise, and a quest for learning more from already available knowledge both in the local area and while traveling. The founder is an operational international airline professional with a sizable network, catering to a viral-based initial expansion model.

Kjeller Innovation is creating companies based on ideas from researcher from ten different research institutes and universities at Kjeller, Ås, Oslo, Buskerud and Vestfold. We are always looking for talented people who are interested in working in startups, be investor in startups, be a board member in a startup or just want to know more about our companies.

Vi leverer styringsløsninger som skal gi virksomheter økt lønnsomhet gjennom bedre styring og kontroll. Vår spesialitet er å forstå kunden sine utfordringer og raskt få på plass en løsning som gir resultater ved å koble forretningforståelse og teknologi. For mindre virksomheter leverer vi portal som kombinerer rapportløsninger med virksomhetskritisk styringsinformasjon. Sammen med den største aktøren innen bolig utvikler vi løsninger hvor vi kombinerer interne data med ekstern informasjon og kunstig intelligens.

Iterate is an ecosystem for digital innovation, and we like to describe ourselves as a company that builds companies. We contribute from A-Z when building, starting with creating concepts based on key insights to launching and improving products whilst living in the marketplace. We find the right team and work toward the company culture that enables us to deliver value to our customers quickly. The key to achieving this is reinvesting all our profits in the ideas of our employees, or selected entrepreneurs. Five years into this strategy, we own shares in fifteen ventures; all of which are showing promising results. Our 70 designers, developers, and product managers just moved into new locations in the center of Oslo. 
Close collaboration with our customers is key to our success. They provide domain know-how, and we provide tools, strategies, and experts. Together we uncover the best way that connects your strategy and idea with the market needs. Our goal is to achieve minimum risk and give our customers the best possible starting point for scaling, on their own, or in continued collaboration.

EpiGuard AS is an innovative Norwegian Medical Technology Company established in 2015 by a group of doctors at the Oslo University Hospital (OUS) together with co-founders Inven2, Eker Group AS, and Hansen Protection AS. EpiGuard has evolved into a highly skilled knowledge-based company. The business model is to develop and manufacture high-end medical equipment for the safe transport of contagious patients. The products will be distributed globally through strategic partners. Currently, the main product is the medical isolation and transportation system, EpiShuttle. The system is developed by clinical experts at OUS, with first-hand experience in providing advanced treatment and transportation of patients with highly infectious diseases, such as Ebola.

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.

BRIK as is a company specialising in new web technology, pedagogy and professional dissemination of knowledge. The team has extensive experience in the dissemination of knowledge with new web technologies and video. Our investors and partners are Innovation Norway, the Norwegian Research Council and several customer partners. The budget for the initial development phase (2013 - ) has been 12 MNOK. Now we are looking for partners for the next stage, where we will commercialize and increase sales.

Vi tør å tenke nytt i en bransje som er preget av umoderne arbeidsformer, og kombinerer tung juridisk kompetanse med markedsledende teknologi. LIGL ble startet for å utfordre den konservative advokatbransjen, og bygger på tre grunnleggende prinsipper, kompetanse, kultur og teknologi – vårt DNA. Gjennom innovativ bruk av teknologi, en moderne forretningsmodell og et unikt arbeidsmiljø, vil vi skape et reelt, effektivt og eksklusivt alternativ til de største advokatfirmaene i Norge. Vi vet at dette vil og må ta tid, men vi vet også at det er denne veien bransjen vil utvikle seg – og vi ønsker å være i forkant. LIGL består av topp kvalifiserte forretningsadvokater med lang fartstid, solid faglig ekspertise og entusiasme for den jobben de gjør. Flere av firmaets advokater kommer fra ledende partnerstillinger i landets største advokatfirmaer. Kundene våre er norske og internasjonale virksomheter. Vi bistår alt fra gründervirksomheter i oppstart, til store selskaper med en lang historie å se tilbake på. Vi tar også oppdrag for privatpersoner innenfor utvalgte rettsområder. Firmaet leverer advokattjenester innen følgende fagområder: - Corporate, strategisk selskapsrettslig rådgivning - Rekonstruksjon & insolvens - Immaterialrett & teknologi - Fast eiendom - Skatt - Tvisteløsning Firmaets advokater er dyktige tverrfaglige forretningsadvokater, og firmaet tar derfor også oppdrag innenfor andre fagområder som naturlig leveres av et kompetent forretningsadvokatfirma, som arbeidsrett, kontraktsrett, entreprise etc.

We start our project in 2017. We develop and offer to the market ecological & sustainable fertilizers made by mineral and organic nature. We cultivate a unique product and engage experience and innovation. By offering a quality product with added value to our customers, we help make a cost-effective solution for horticulture and agriculture.  We are happy to be engaged in the optimization of performance for allied businesses and private customers.

We are disrupting heavy construction. They build roads and infrastructure for billions of NOK/USD/EUR. But paper and old-school applications are still the things when it comes to data collection and reporting. We have cracked some of the code and have landed contracts with some of the biggest construction companies in the world. Are you the kind of person that would like to join a startup in the beginning? Take charge of your field, and help us become the global leader that we have the potential to be. All that stands between us and international success is us - and you. Can we execute well enough? We have a base product. The market has already accepted us. Do you want to join the core team? Reach out to us! We are especially on the lookout for the following areas. But please reach out if you think you have anything of value to us! - UX / front-end (future stack is react-based, you will help us mold it) - Native gurus (iOS/Android)

Inspera is the leading European high-stakes digital examination platform and end-to-end solution for governments, awarding bodies, higher education institutions as well as schools. On a mission to re-invent educational assessment for the 21st century, we offer the most innovative, reliable and secure service as well as the expertise needed digitise large-scale examinations.